Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Idera Makes Leadership Additions

This article was originally published in Scrip

Executive Summary

Idera Pharmaceuticals, Inc., has made several leadership additions: appointing Mark J. Cornfeld vice president and medical lead for oncology; Kirsten L. Gruis senior medical director for rare diseases; Tanya N. Lewis vice president of regulatory affairs and quality assurance; and John J. Kirby vice president of corporate accounting. Cornfeld recently held various oncology leadership roles at GlaxoSmithKline and prior to this he was at Johnson & Johnson and Hoffman-LA Roche. Most recently Gruis was director, clinical development at Alnylam Pharmaceuticals and before this she was neuromuscular clinical lead at Pfizer Inc. Lewis has been vice president of regulatory affairs and medical writing at Tesaro, Inc before which she held regulatory roles at Seaside Therapeutics, Vion Pharmaceutical, Millennium Pharmaceuticals and Genzyme Corporation. Finally, Kirby joins Idera from Endo Pharmaceuticals, where most recently he was assistant controller.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC063854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel